免疫系统疾病影响着全世界数以亿计的人，并可能严重影响生活质量，甚至是预期寿命1，2，3。此类令人衰弱的疾病，这其中包含影响关节的疾病（例如类风湿性关节炎、强制性脊柱炎和银屑病关节炎）、皮肤（如银屑病）和肠道（如克罗恩病和溃疡性结肠炎）的疾病。
山德士是支持风湿病医生、皮肤病医生和肠胃病一生的长期合作伙伴，全力推进病人护理。我们在生物类似药领域的专业知识及经验已经得到证实，在这一领域提供高质量、可负担的药物。
我们致力于提供改变生活的免疫学疗法，并拥有强大的生物仿制免疫学产品组合，其中包含Erelzi®4、Hyrimoz®5、Zessly®6，和Rixathon®7.
- Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012 Dec;18(13 Suppl):S295-302.
- World Health Organization. Global report on psoriasis 2016. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf [Accessed March 2021]
- Gladman D et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64:ii14-ii17 doi:10.1136/ard.2004.032482
- European Medicines Agency. Erelzi® Summary of Product Characteristics. Available from: https://www.ema.europa.eu/medicines/human/EPAR/Erelzi [Accessed March 2021]
- European Medicines Agency. Hyrimoz® Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz [Accessed March 2021]
- European Medicines Agency. Zessly® Summary of Product Characteristics. Available https://www.ema.europa.eu/en/medicines/human/EPAR/zessly [Accessed March 2021]
- European Medicines Agency. Rixathon® Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rixathon [Accessed March 2021]